Visit our Expo - Redox and Inflammation signaling 2012

Santourlidis S, Kimura F, Fischer J, Schulz WA (2004) Suppression of clonogenicity by the PCNA-binding
domain of mammalian Dnmt1. Biochem. Cell Biol. 82, 589-596
Raschke S, Balz V, Efferth T, Schulz WA, Florl AR (2005) Homozygous deletions of CDKN2A caused by
alternative mechanisms in different human cancer cell lines. Genes Chromosomes Cancer, 42, 58-67
Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA (2005) Hedgehog signaling in normal urothelial cells
and in urothelial carcinoma cell lines. J. Cell. Physiol. 203, 372-377
Hoffmann MJ, Florl AR, Seifert HH, Schulz WA (2005) Multiple mechanisms inactivating CDKN1C in bladder
cancer. Int. J. Cancer 114, 406-413
Kindich R, Florl AR, Jung V, Engers R, Müller M, Schulz WA, Wullich B (2005) Application of a modified
real-time PCR technique for relative gene copy number quantification to the determination of the relationship
between NKX3.1 loss and MYC gain in prostate cancer. Clin. Chem. 51, 649-652
Cronauer MV, Schulz WA, Ackermann R, Burchardt M (2005) Effects of WNT/#-catenin pathway activation on
signaling through T-cell factor (TCF) and androgen receptor in prostate cancer cell lines. Int. J. Oncol. 26,
1003-1040
Rahnenführer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, Wullich B, Lengauer T (2005)
Estimating cancer survival and clincial outcome based on genetic tumor progression scores. Bioinformatics 21,
2438-2446
Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA (2005) Amplification and overexpression of the ID4 gene at
6p22.3 in bladder cancer. BMC Mol. Cancer 4, 16 (online)
Sarbia M, Geddert H, Kiel S, Kandemin Y, Schulz WA, Vossen S, Zotz RD, Willers R, Baldus SE, Schneider
PM, Gabbert HE (2005) Methylenetetrahydrofolate reductase C677T polymorphism and risk of adenocarcinoma
of the upper gastrointestinal tract. Scand. J. Gastroenterol. 40, 109-111
Laner T, Schulz WA, Engers R, Müller M, Florl AR (2005) Hypomethylation of the XIST promoter in prostate
cancer. Oncol. Res. 15, 257-264
Kindich R, Florl AR, Kamradt J, Lehmann J, Müller M, Wullich B, Schulz WA (2005) Relationship of NKX3.1
and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. Eur. Urol., in press
Wethkamp N, Ramp U, Geddert H, Schulz WA, Florl AR, Suschek CV, Hassan M, Gabbert HE, Mahotka C
(2006) Expression of Death-Associated Protein Kinase during tumor progression of human renal cell
carcinomas: clues for hypermethylation-independent mechanisms of inactivation. Eur. J. Cancer, in press
Schulz WA, Seifert HH (2004) DNA methylation in urological cancers. In: “DNA methylation and cancer
therapy” (Szyf M, Hg.), pp.42-58, Landes Biosciences
Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, De La Taille A, Ackermann R, Burchardt M (2003)
The androgen receptor in hormone-refractory prostate cancer: Relevance of different mechanisms of androgen
receptor signaling. Int. J. Oncol. 23, 1095-1102
Grimm MO, Hartmann FH, Schulz WA (2004) Microarrays: Technik und Potenzial beim Prostatakarzinom.
Urologe 43, 653-658
Schulz WA, Müller M (2004) Molekulare Karzinogenese des Prostatakarzinoms. in: Borchers H, Jakse G (eds)
“Die Therapie des Prostatakarzinoms: Die Zukunft hat begonnen”. Akt. Onkol. 122, 39-53.
Hoffmann MJ, Schulz WA (2005) Causes and consequences of DNA hypomethylation in human cancer.
Biochem. Cell Biol. 83, 296-321
Schulz WA (2005) Qualified promise: DNA methylation assays for cancer detection and classification
(editorial). J. Biomed. Biotechnol. 3, 227-229
Schulz WA, Steinhoff C, Florl AR (2005) Methylation of endogenous human retroelements in health and
disease. Curr. Topics Microbiol. Immunol., in press
Schulz WA (2006) L1 retrotransposon in human cancers. J. Biomed. Biotechnol., in press
- 92 -